Thursday, June 14, 2018

Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis

With a $10 billion market cap, it’s hard to call Alnylam (ALNY) overlooked, but I do believe the shares of this maturing biotech are undervalued as the company approaches a window that should see multiple new product approvals through 2020. Most recently, Alnylam has offered up some data that suggest growing opportunities outside its core amyloidosis programs.

Read more here:
Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis

No comments: